Multimodal Imaging Market Report 2026

The multimodal imaging market size has grown strongly in recent years. It will grow from $4.32 billion in 2025 to $4.61 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to growth of advanced diagnostic imaging, rising cancer screening programs, expansion of hospital imaging infrastructure, improvements in detector technology, higher clinical imaging demand.

The multimodal imaging market size is expected to see strong growth in the next few years. It will grow to $6 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increase in precision diagnostics demand, rising chronic disease burden, adoption of AI imaging analytics, growth of hybrid imaging systems, expansion of imaging as a service. Major trends in the forecast period include hybrid pet mr imaging systems, integrated multi modality diagnostics, AI assisted image fusion, cloud based imaging analytics, advanced multimodal visualization software.

The growing need for early and precise disease diagnosis is anticipated to boost the growth of the multimodal imaging market in the future. Early and accurate disease diagnosis involves identifying illnesses at an early stage with high precision using medical data and advanced technologies, enabling timely treatment and improved patient outcomes. The increasing emphasis on early and accurate diagnosis is driven by individuals seeking prompt and precise detection of diseases for better treatment results, allowing healthcare professionals to identify conditions much earlier than in the past. Multimodal imaging supports early and accurate diagnosis by enabling the integration of multiple medical imaging techniques to detect diseases more effectively. For example, in October 2024, according to the National Health Service England, a UK-based public organization, by March 2024 early diagnosis rates were 2.4 percentage points above pre-pandemic levels and 0.8 percentage points higher than the previous year based on Rapid Cancer Registration Data. Therefore, the growing demand for early and accurate disease diagnosis is strengthening the growth of the multimodal imaging market.

Key companies operating in the multimodal imaging market are concentrating on innovations in artificial intelligence and machine learning for image analysis and interpretation, such as AI-assisted image segmentation, which enables automated identification of anatomical structures and regions of interest across various imaging modalities. AI-assisted image segmentation refers to the application of artificial intelligence algorithms to automatically divide images into meaningful regions, a task that traditionally required manual outlining by human specialists. For instance, in September 2025, Revvity, Inc., a US-based company specializing in preclinical imaging solutions, launched Living Image Synergy AI multimodal analysis software. This software provides a unified AI-enabled platform for seamless analysis of in vivo imaging data across optical, microCT, ultrasound, and additional modalities. It reduces data inconsistencies by centralizing workflows and removing reliance on multiple standalone tools. It also integrates advanced AI algorithms to automate image segmentation and region-of-interest quantification, improving accuracy and reproducibility. Intuitive co-registration and automated processes further reduce manual effort and analysis time.

In November 2024, CrestOptics S.p.A., an Italy-based provider of advanced microscopy technologies, partnered with Tomocube Inc. to merge complementary imaging methods into a unified multimodal system. Through this collaboration, both companies planned to co-develop and commercialize the HT X1 Plus imaging platform, which combines holotomography for label-free 3D cellular visualization with spinning-disk confocal fluorescence microscopy. This partnership aims to allow researchers to collect both structural and molecular data from the same samples, improving workflows in live-cell imaging, tissue analysis, and developmental biology. Tomocube Inc. is a South Korea-based company specializing in holotomography imaging solutions for quantitative 3D cellular and tissue analysis.

Major companies operating in the multimodal imaging market are Samsung Medison Co. Ltd., Analogic Corporation, Alcon Inc., Hologic Inc., Sofie Biosciences Inc., ShanghAI United Imaging Healthcare Co. Ltd., Topcon Corporation, Agfa-Gevaert Group, Heidelberg Engineering GmbH, Optos plc, RefleXion Medical Inc., Neusoft Corporation, Infraredx Inc., MinFound Medical Systems Co. Ltd., Neusoft Medical Systems Co. Ltd., Spectrum Dynamics Medical LLC, Konica Minolta Healthcare Americas Inc., Esaote S.p.A., MR Solutions Ltd., MILabs B.V., NIDEK Co. Ltd., Kowa Company Ltd., and Positron Corporation.

Tariffs on imaging equipment, precision sensors, and radiological components are raising procurement and installation costs in the multimodal imaging market. High value hardware segments such as PET, CT, and MR hybrid systems are most affected due to cross border component sourcing. Hospitals and diagnostic centers in import dependent regions face longer replacement cycles and higher capital budgets. Service and software layers are less exposed but still affected through bundled system pricing. These tariffs are also motivating regional manufacturing partnerships and localized assembly of imaging systems.

The multimodal imaging market research report is one of a series of new reports that provides multimodal imaging market statistics, including multimodal imaging industry global market size, regional shares, competitors with a multimodal imaging market share, detailed multimodal imaging market segments, market trends and opportunities, and any further data you may need to thrive in the multimodal imaging industry. This multimodal imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multimodal imaging refers to the sector focused on developing and delivering imaging systems that combine multiple imaging modalities, such as magnetic resonance imaging, computed tomography, positron emission tomography, and ultrasound, to provide comprehensive diagnostic and analytical insights. These systems enhance visualization, enable accurate diagnosis, and improve monitoring by integrating multiple types of imaging data.

The primary products of multimodal imaging include multimodal imaging equipment, reagents, and software. Multimodal imaging equipment refers to advanced systems that combine multiple imaging technologies to deliver comprehensive anatomical and functional insights for precise diagnosis and treatment planning. These solutions utilize technologies such as positron emission tomography combined with computed tomography, single photon emission computed tomography with computed tomography, positron emission tomography with magnetic resonance imaging, and other systems. The applications include oncology, cardiology, neurology, ophthalmology, musculoskeletal conditions, and other clinical areas. The end users include hospitals, diagnostic imaging centers, and other healthcare facilities employing advanced imaging tools for diagnosis and research.

The multimodal imaging market consists of revenues earned by entities by providing services such as installation and commissioning, system integration, maintenance and repair, calibration and quality assurance, software support and updates, imaging data analysis, cloud data management, training and education, imaging as a service and consulting and workflow optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The multimodal imaging market includes sales of magnetic resonance imaging (MRI) scanners, computed tomography (CT) scanners, ultrasound systems, optical imaging systems, multimodal imaging systems, imaging detectors and radiofrequency coils, imaging workstations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.